VisCardia, Inc., a Portland, Oregon-based medical device company developing a novel chronic heart failure therapy, completed series B financing.
It simultaneously obtained assets and technology rights from Inovise Medical, Inc., with a combined aggregate value of $12.5M, to continue development of its proprietary implantable heart failure therapy device.
The round was led by Kinetic Capital Partners of Vancouver BC.
Led by Peter Bauer, President and Chief Executive Officer, VisCardia provides a proprietary implantable system that chronically stimulates the thoracic cavity musculature to mechanically augment cardiac systole and diastolic filling. The therapy is targeted for the majority of heart failure patients with reduced ejection fraction and normal ventricular electrical conduction.
Consistent with the company’s objectives, Dr. Michael Mirro M.D. has joined VisCardia as its Director of Medical Affairs.
Dr. Mirro is board certified in internal medicine, cardiovascular disease, cardiac electrophysiology, and geriatrics. He is a Certified Cardiac Device Specialist (IBHRE), and a Fellow of the American College of Physicians, the American Heart Association, the American College of Chest Physicians, and the American College of Cardiology (ACC).
He has conducted clinical research studies as a principal investigator for over 100 trials and has published over 40 scientific articles and book chapters.